Sinovation Medical Launches Q300: China's First Miniature Neurosurgical Robot for Grassroots Accessibility

With the rise and maturation of domestically produced robotic technologies, micro-robotic stereotactic devices—distinguished by their low cost, automation, and comprehensive coverage—are gradually emerging to serve a broader base of physicians and patients across China.

Sinovation’s SR1 series, a high-end 3D structured-light neurosurgical robot jointly developed with Tsinghua University and dual-certified by the NMPA and FDA, has secured a leading position in the market. In addition, Sinovation has developed and launched the Q300 series, a versatile, miniaturized neurosurgical robot characterized by its lightweight and compact design. This system enables standardized, streamlined minimally invasive puncture procedures in brain surgery, breaking through the application limitations of traditional stereotactic head frames. It reduces preoperative preparation time by approximately one hour, while meeting the dual demands for efficiency and positioning accuracy in emergency surgeries for hypertensive intracerebral hemorrhage.

Sinovation’s Q300 Microsurgical Robotic System for Neurosurgery has pioneered China’s first integrated solution combining navigation and directional guidance. Its performance and safety have been fundamentally improved compared to similar products, placing it at an internationally leading technological level with significant clinical value. The Q300 was included in the “Special Review Procedure for Innovative Medical Devices” (Innovation Channel) by the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA) and received NMPA market approval in early 2022.

On Tuesday, December 26, at 19:30, the 41st session of VCBeat Select New Product Appreciation will featureDong Yi, Board Secretary of Sinovation; Wang Peng, Product Director of the Marketing Department at SinovationPresenting relevant product introductions.

Automated Precision Targeting

The Q300 integrates a top-tier infrared optical localizer, a high-precision robotic arm, and advanced image registration algorithms, achieving sub-millimeter (<1 mm) positioning accuracy. It supports various minimally invasive procedures, including minimally invasive drainage for intracerebral hemorrhage and biopsy of intracranial lesions. Its exceptional positioning accuracy serves as a critical safeguard for surgical safety.

Compact and space-saving

The micro-surgical robot is only as large as an adult's palm, occupying no operating room or surgeon workspace. It can freely adjust its height and angle relative to the surgical table during procedures, ensuring the most comfortable operative experience for the surgeon at all times.

Simple and time-saving, a complete replacement for traditional stereotactic head frames

Eliminating the need for preoperative marker placement or metal localization head frames, as well as additional preoperative localization imaging scans, the robot automatically “aims” at the target strictly according to the surgical plan formulated by the physician during surgery. This achieves rapid and precise localization of intracranial targets, reduces preoperative preparation time by approximately one hour, and significantly enhances surgical efficiency.

More suitable for promotion and application in primary healthcare institutions

The Q300 neurosurgical microsurgical robot, independently developed and manufactured by Sinovation with full proprietary intellectual property rights, offers a lower acquisition cost compared to large-scale surgical robotic systems. It is better suited for neurosurgery departments in China’s extensive network of primary and secondary hospitals to perform minimally invasive treatments for common conditions such as cerebral hemorrhage.

Scan the QR code on the poster to add our assistant and reserve a spot for the live stream.

Dong Yi

Sinovation | Board Secretary

Graduated from the School of Economics and Management at Tsinghua University, previously served at multiple companies listed on the Main Board and the STAR Market. Currently primarily responsible for investment and financing, investor relations (IR), and capital operations at Sinovation.

Wang Peng

Sinovation | Product Director, Marketing Department

Master of Medicine, with over ten years of experience in medical device marketing. Currently primarily responsible for the national market operations and promotion of innovative medical technologies and products, including the Sinovation neurosurgical robot and surgical navigation systems.

Huake Jingzhun (Beijing) Medical Technology Co., Ltd., established in 2015 and located in the Zhongguancun Medical Device Industrial Park, specializes in the research and development, manufacturing, sales, and technical services of high-end medical devices such as neurosurgical robotic systems. The company has received numerous honors, including being recognized as a winner in the latest round of key tasks for artificial intelligence industrial innovation unveiled by the Ministry of Industry and Information Technology (MIIT), the Chinese Medical Science and Technology Award, the Huaxia Medical Award, designation for the first set of major technical equipment by MIIT and Zhongguancun, National High-Tech Enterprise, National Specialized and Sophisticated “Little Giant” Enterprise, National Intellectual Property Advantage Enterprise, and serving as the national focal point for standardization technology in medical robots.

Adhering to an innovation-driven development strategy, the company is committed to advancing the industrialization of surgical robots and innovative medical devices. Its product portfolio comprises more than ten innovative medical devices, including the SR1 series high-end neurosurgical robot with 3D structured light, the Q300 series universal neurosurgical robot, the NS series neuronavigation systems, the LITT laser ablation system, and the HKHS intracranial electrode series. Notably, the SR1 series neurosurgical robot is the only product in China to have received dual certification from both the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). It has been deployed in over 200 medical institutions across China, ranking first in national market share.

In the future, guided by the “Healthy China Strategy” and the “China Brain Science Initiative,” the company will remain committed to addressing clinical needs, collaborating closely with physicians, and leveraging innovative products such as multi-level sensing robots and multimodal imaging planning software. By implementing a comprehensive innovation strategy across the entire industry chain—integrating high-end medical devices, high-value consumables, and technical services—the company aims to make significant contributions to advancing China’s neurosurgical diagnosis and treatment capabilities to a globally leading position.

“Artery Select New Product Launch” is a livestream series under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of innovative medical products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively contact the assistant.)